GW Pharmaceuticals PLC- (NASDAQ:GWPH) Downgraded to “Sell” at ValuEngine

ValuEngine downgraded shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) from a hold rating to a sell rating in a report released on Monday, ValuEngine reports.

Several other brokerages have also commented on GWPH. Piper Jaffray Companies lifted their price objective on GW Pharmaceuticals PLC- from $185.00 to $210.00 and gave the stock an overweight rating in a report on Tuesday, May 7th. Cowen reaffirmed a buy rating and issued a $200.00 price objective on shares of GW Pharmaceuticals PLC- in a report on Friday, July 26th. Morgan Stanley lifted their price objective on GW Pharmaceuticals PLC- to $238.00 and gave the stock an overweight rating in a report on Wednesday, August 7th. Zacks Investment Research lowered GW Pharmaceuticals PLC- from a buy rating to a hold rating in a report on Wednesday, August 7th. Finally, Oppenheimer lifted their price objective on GW Pharmaceuticals PLC- from $234.00 to $239.00 and gave the stock a buy rating in a report on Wednesday, August 7th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $212.70.

Shares of GWPH opened at $152.92 on Monday. The company has a quick ratio of 7.59, a current ratio of 8.31 and a debt-to-equity ratio of 0.03. GW Pharmaceuticals PLC- has a one year low of $90.14 and a one year high of $196.00. The business has a fifty day moving average of $166.13 and a 200 day moving average of $166.95.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.78) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.74) by $0.96. GW Pharmaceuticals PLC- had a negative return on equity of 38.09% and a negative net margin of 101.45%. The company had revenue of $72.04 million during the quarter, compared to analyst estimates of $37.28 million. During the same quarter in the previous year, the company posted ($0.25) earnings per share. GW Pharmaceuticals PLC-‘s revenue was up 2096.3% compared to the same quarter last year. On average, research analysts predict that GW Pharmaceuticals PLC- will post -3.84 EPS for the current year.

In other GW Pharmaceuticals PLC- news, Director William A. Waldegrave sold 3,576 shares of the business’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $15.00, for a total transaction of $53,640.00. Following the completion of the sale, the director now owns 3,576 shares of the company’s stock, valued at $53,640. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Scott M. Giacobello sold 4,224 shares of the business’s stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $14.52, for a total value of $61,332.48. The disclosure for this sale can be found here. Insiders have sold 378,288 shares of company stock valued at $5,710,525 in the last three months. 3.60% of the stock is currently owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the business. Horan Capital Advisors LLC. bought a new stake in GW Pharmaceuticals PLC- during the first quarter valued at about $25,000. Kavar Capital Partners LLC bought a new stake in GW Pharmaceuticals PLC- during the second quarter valued at about $26,000. Prestige Wealth Management Group LLC bought a new stake in GW Pharmaceuticals PLC- during the second quarter valued at about $28,000. Exane Derivatives bought a new stake in GW Pharmaceuticals PLC- during the first quarter valued at about $28,000. Finally, Pathstone Family Office LLC bought a new stake in GW Pharmaceuticals PLC- during the second quarter valued at about $29,000. 78.92% of the stock is owned by institutional investors and hedge funds.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Read More: Average Daily Trade Volume Explained

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.